Simon TG, Duberg A-S, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med 2020;382:12 de marzo. [Ref.ID 103565]

Dimmitt SB, Stampfer HG. Polypill for prevention of cardiovascular diseases. Lancet 2020;395:413-4. [Ref.ID 103520]

Schuster BC, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018. PLOS Medicine 2019;16:10 de septiembre. [Ref.ID 103247]

Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019;394:24 de agosto. [Ref.ID 103246]

Rathi S, Kumar P. Drug-induced liver injury — Types and phenotypes. N Engl J Med 2019;381:3 de octubre. [Ref.ID 103189]

Anónimo. Hepatitis C medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to rare occurrence of serious liver injury in some patients with advanced liver disease. FDA MedWatch alert 2019:28 de agosto. [Ref.ID 103166]

Jeong S, Tchoe HJ, Shin JY. All-cause mortality associated with tramadol use: a case-crossover study. Drug Saf 2019;42:junio. [Ref.ID 103119]

Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]

Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Baah JO, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li P-Z, Hill PC, Schwartzman K, Benedetti A, Menzies D. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102756]

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Baah JO, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata KE, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion-M-J, Li P-Z, Schwartzman K, Benedetti A. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102755]

Samper E. ¿Y por qué no una farmacéutica pública?. eldiario.es 2018:19 de abril. [Ref.ID 102705]

Anónimo. Acide obéticholique et cholangite biliaire primitive. Prescrire 2018;38:326-7. [Ref.ID 102652]

Anónimo. Flupirtine: Serious liver problems. European Union. WHO Drug Information 2018;32:21. [Ref.ID 102625]

Anónimo. Artemisia annua soft gel capsules: Reports of liver damage. New Zealand. WHO Drug Information 2018;32:20. [Ref.ID 102624]

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, for the GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:17 de mayo. [Ref.ID 102609]

Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793. [Ref.ID 102549]

Anónimo. Esmya® : vigilar la función hepática y no iniciar nuevos tratamientos como medidas cautelares. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:9 de febrero. [Ref.ID 102526]

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

Mole B. “Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Ars Technica 2018:12 de abril. [Ref.ID 102511]

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]